About ascletis pharma inc - ASCLF
Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The company was founded by Jinzi Jason Wu and is headquartered in Hangzhou, China.
ASCLF At a Glance
Ascletis Pharma, Inc.
HIPARK, 198 Qidi Road
Hangzhou, Zhejiang 311200
| Phone | N/A | Revenue | 282.12K | |
| Industry | Biotechnology | Net Income | -50,063,657.26 | |
| Sector | Health Technology | 2025 Sales Growth | 58.251% | |
| Fiscal Year-end | 12 / 2026 | Employees | 202 | |
| View SEC Filings |
ASCLF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5,044.414 |
| Price to Book Ratio | 5.23 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -17.763 |
| Enterprise Value to Sales | 4,082.849 |
| Total Debt to Enterprise Value | 0.001 |
ASCLF Efficiency
| Revenue/Employee | 1,396.63 |
| Income Per Employee | -247,839.887 |
| Receivables Turnover | 0.149 |
| Total Asset Turnover | 0.001 |
ASCLF Liquidity
| Current Ratio | 15.054 |
| Quick Ratio | 15.039 |
| Cash Ratio | 14.898 |
ASCLF Profitability
| Gross Margin | -842.702 |
| Operating Margin | -23,853.943 |
| Pretax Margin | -17,720.611 |
| Net Margin | -17,745.562 |
| Return on Assets | -17.064 |
| Return on Equity | -18.333 |
| Return on Total Capital | -18.039 |
| Return on Invested Capital | -18.316 |
ASCLF Capital Structure
| Total Debt to Total Equity | 0.267 |
| Total Debt to Total Capital | 0.266 |
| Total Debt to Total Assets | 0.25 |
| Long-Term Debt to Equity | 0.118 |
| Long-Term Debt to Total Capital | 0.118 |